Readystate Asset Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$673K Buy
+11,100
New +$647K 0.03% 525
2025
Q2
Sell
-50,900
Closed -$3.1M 651
2025
Q1
$3.1M Buy
50,900
+1,400
+3% +$81.6K 0.1% 217
2024
Q4
$2.8M Sell
49,500
-158,500
-76% -$8.86M 0.09% 240
2024
Q3
$10.8M Buy
+208,000
New +$9.76M 0.2% 215
2024
Q2
Sell
-341,800
Closed -$18.5M 742
2024
Q1
$18.5M Buy
341,800
+339,600
+15,436% +$17.3M 0.26% 57
2023
Q4
$113K Buy
+2,200
New +$115K ﹤0.01% 577

Other funds holding BMY

Readystate Asset Management's BMY Position: Q1 2026 in Review

Readystate Asset Management sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 788,399 shares — an estimated $46M sold.

Readystate Asset Management first reported a position in BMY in Q2 2023 and held it in 3 quarters. The position peaked at $42.5M in Q4 2025. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Readystate Asset Management reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
  • Readystate Asset Management sold 788,399 Bristol-Myers Squibb shares in Q1 2026, an estimated $46M.
  • Readystate Asset Management first reported a position in Bristol-Myers Squibb in Q2 2023 and held it in 3 quarters.
  • Readystate Asset Management's Bristol-Myers Squibb position peaked at $42.5M in Q4 2025.
  • 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Readystate Asset Management's 13F filing for Q1 2026, filed 15 May 2026.